Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients

Noce A, Albanese M, Marrone G, Di Lauro M, Pietroboni Zaitseva A, Palazzetti D, Guerriero C, Paolino A, Pizzenti G, Di Daniele F, Romani A, D'Agostini C, Magrini A, Mercuri NB, Di Daniele N. Pharmaceuticals, 2021; 14(4):336.

ReviewHumansOther animals

Design: Review
What was measured: Why ultramicronised palmitoylethanolamide might help as an add-on treatment in COVID-19: its proposed effects on immune response and inflammation, and what pharmacokinetic data exist

What the authors reported

Drawing on earlier laboratory and clinical work, the authors propose that palmitoylethanolamide's effects on immune response and inflammation could limit organ damage in COVID-19, while noting pharmacokinetic data are limited. They note the FDA had authorised a clinical trial of ultramicronised PEA as an add-on therapy for SARS-CoV-2 infection. The article reports no patient data.

Limits of this study

A hypothesis paper with no new data. The same group later ran a small study in patients: see Albanese 2022. For a placebo-controlled trial, see Fessler 2022, which found a difference in one of six main blood markers. Funding and conflict statements were not visible on the page checked.

Source

doi:10.3390/ph14040336

Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.